医学
腹膜炎
腹膜透析
重症监护医学
猫传染性腹膜炎
内科学
疾病
传染病(医学专业)
2019年冠状病毒病(COVID-19)
作者
Philip Kam‐Tao Li,Kai Ming Chow,Yeoungjee Cho,Stanley Fan,Ana Elizabeth Figueiredo,Tess Harris,Talerngsak Kanjanabuch,Yong-Lim Kim,Magdalena Madero,Jolanta Małyszko,Rajnish Mehrotra,Ikechi G. Okpechi,Jeff Perl,Beth Piraino,Naomi Runnegar,Isaac Teitelbaum,Jennifer Ka-Wah Wong,Xueqing Yu,David W. Johnson
标识
DOI:10.1177/08968608221080586
摘要
Peritoneal dialysis (PD)-associated peritonitis is a serious complication of PD and prevention and treatment of such is important in reducing patient morbidity and mortality. The ISPD 2022 updated recommendations have revised and clarified definitions for refractory peritonitis, relapsing peritonitis, peritonitis-associated catheter removal, PD-associated haemodialysis transfer, peritonitis-associated death and peritonitis-associated hospitalisation. New peritonitis categories and outcomes including pre-PD peritonitis, enteric peritonitis, catheter-related peritonitis and medical cure are defined. The new targets recommended for overall peritonitis rate should be no more than 0.40 episodes per year at risk and the percentage of patients free of peritonitis per unit time should be targeted at >80% per year. Revised recommendations regarding management of contamination of PD systems, antibiotic prophylaxis for invasive procedures and PD training and reassessment are included. New recommendations regarding management of modifiable peritonitis risk factors like domestic pets, hypokalaemia and histamine-2 receptor antagonists are highlighted. Updated recommendations regarding empirical antibiotic selection and dosage of antibiotics and also treatment of peritonitis due to specific microorganisms are made with new recommendation regarding adjunctive oral N-acetylcysteine therapy for mitigating aminoglycoside ototoxicity. Areas for future research in prevention and treatment of PD-related peritonitis are suggested.
科研通智能强力驱动
Strongly Powered by AbleSci AI